The estimated Net Worth of James George Robinson is at least $940 Tisíc dollars as of 2 May 2022. Mr. Robinson owns over 1,151,515 units of Nymox Pharmaceutical Corp stock worth over $940,413 and over the last 9 years he sold NYMX stock worth over $0. In addition, he makes $0 as Independent Director at Nymox Pharmaceutical Corp.
James has made over 85 trades of the Nymox Pharmaceutical Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 1,151,515 units of NYMX stock worth $1,900,000 on 2 May 2022.
The largest trade he's ever made was buying 1,151,515 units of Nymox Pharmaceutical Corp stock on 2 May 2022 worth over $1,900,000. On average, James trades about 29,659 units every 29 days since 2015. As of 2 May 2022 he still owns at least 4,702,065 units of Nymox Pharmaceutical Corp stock.
You can see the complete history of Mr. Robinson stock trades at the bottom of the page.
James G. Robinson serves as Independent Director of the Company. CEO of Morgan Creek Productions, which for over 25 years has continued to be one of the leading and most successful independent production entities in the film business. Under Robinson’s leadership, Morgan Creek has produced an assortment of highly successful and critically acclaimed feature films.
James Robinson is 84, he's been the Independent Director of Nymox Pharmaceutical Corp since 2015. There are no older and 8 younger executives at Nymox Pharmaceutical Corp.
James's mailing address filed with the SEC is 10 EAST LEE STREET, SUITE 2705, BALTIMORE, MD, 21202.
Over the last 9 years, insiders at Nymox Pharmaceutical Corp have traded over $4,394,000 worth of Nymox Pharmaceutical Corp stock and bought 2,534,915 units worth $5,846,809 . The most active insiders traders include James George Robinson, Paul Averback a Erik Danielsen. On average, Nymox Pharmaceutical Corp executives and independent directors trade stock every 27 days with the average trade being worth of $9,606. The most recent stock trade was executed by James George Robinson on 2 May 2022, trading 1,151,515 units of NYMX stock currently worth $1,900,000.
nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.
Nymox Pharmaceutical Corp executives and other stock owners filed with the SEC include: